<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药云端工作室 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-17T20:46:18+08:00</updated>
  <subtitle>医药行业领先的智库，连接政策与市场的桥梁</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【持续跟踪99周】本周新增9品种过评，酮咯酸氨丁三醇片、乳酸环丙沙星氯化钠注射液迎首家</title>
    <updated>2021-01-17T18:19:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/V-Th6tkQCAr_8WbzVcH95A</id>
    <link href="https://mp.weixin.qq.com/s/V-Th6tkQCAr_8WbzVcH95A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年，299位药企高管离职（附名单）</title>
    <updated>2021-01-17T18:19:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/4abC2WOGX-ZHH5NFA8fFAQ</id>
    <link href="https://mp.weixin.qq.com/s/4abC2WOGX-ZHH5NFA8fFAQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批国采将于2月3日开标；2021年销量前500个品种是集采重点；多省要求企业“自首”失信行为｜云端周报</title>
    <updated>2021-01-17T18:19:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/KfrwHKNdRyjoFDRAH9c24Q</id>
    <link href="https://mp.weixin.qq.com/s/KfrwHKNdRyjoFDRAH9c24Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021：集采及医保目录准入，重新定义医药行业发展</title>
    <updated>2021-01-16T17:47:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/tM8nzNx5PbLp0AHYReY8hg</id>
    <link href="https://mp.weixin.qq.com/s/tM8nzNx5PbLp0AHYReY8hg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>6726个品种被取消采购！</title>
    <updated>2021-01-16T17:47:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/XO7RqFVliwCLMJGRJQsEtg</id>
    <link href="https://mp.weixin.qq.com/s/XO7RqFVliwCLMJGRJQsEtg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批国采正式开启！45个品种纳入，2月3日开标</title>
    <updated>2021-01-15T18:03:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/2WWnPdPHE8cN1ysboa8jvg</id>
    <link href="https://mp.weixin.qq.com/s/2WWnPdPHE8cN1ysboa8jvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>注意！涉严重不良反应，2款药品被召回，注销药品注册批件！</title>
    <updated>2021-01-15T18:03:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/TRSULL4f4vV9-oIYIsBBNA</id>
    <link href="https://mp.weixin.qq.com/s/TRSULL4f4vV9-oIYIsBBNA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>集采结果出炉：安徽60品种中选，省际联盟2品种议价入围</title>
    <updated>2021-01-15T18:03:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/HW4IBRTPPyAPWfqx35DmOA</id>
    <link href="https://mp.weixin.qq.com/s/HW4IBRTPPyAPWfqx35DmOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医保基金专项治理启动，5类问题需注意</title>
    <updated>2021-01-15T18:03:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/4tdq8vCv2ueQLBlbwG7qpg</id>
    <link href="https://mp.weixin.qq.com/s/4tdq8vCv2ueQLBlbwG7qpg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医保谈判品种大幅降价挂网，礼来、豪森打响第一炮！</title>
    <updated>2021-01-14T17:43:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/shojO-WggiWXWU_ae_WDUA</id>
    <link href="https://mp.weixin.qq.com/s/shojO-WggiWXWU_ae_WDUA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药品价格管理办法或将出台</title>
    <updated>2021-01-14T17:43:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/nPHm3EKcX5I6kNDvmt1zWA</id>
    <link href="https://mp.weixin.qq.com/s/nPHm3EKcX5I6kNDvmt1zWA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新一轮拟优先审评审批名单出炉，恒瑞、思路迪/康宁杰瑞、苏庇医药等在列！</title>
    <updated>2021-01-14T17:43:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/7tQlEVHZ-IwHx8J6t9VGDQ</id>
    <link href="https://mp.weixin.qq.com/s/7tQlEVHZ-IwHx8J6t9VGDQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一图读懂《药品上市后变更管理办法（试行）》</title>
    <updated>2021-01-14T17:43:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/9n8Fy8Ze3iT_XZrb-tWYUw</id>
    <link href="https://mp.weixin.qq.com/s/9n8Fy8Ze3iT_XZrb-tWYUw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再次强调！2021集采，销量前500的品种是重点！</title>
    <updated>2021-01-13T18:33:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/15VpXe7mkmG2bXk1KSU6dA</id>
    <link href="https://mp.weixin.qq.com/s/15VpXe7mkmG2bXk1KSU6dA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>注意！多省医保局限期等你主动报告失信行为，含贿赂、垄断、价格和涉税违法，逾期不报撤网！</title>
    <updated>2021-01-13T18:33:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/QKWzcCznFyGyqj0M7ICWUw</id>
    <link href="https://mp.weixin.qq.com/s/QKWzcCznFyGyqj0M7ICWUw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>湖北明确：8类药品采购准入、价格及挂网规则</title>
    <updated>2021-01-13T18:33:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/LZJsvRBSNbtEMoJJkdY0kA</id>
    <link href="https://mp.weixin.qq.com/s/LZJsvRBSNbtEMoJJkdY0kA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>突发！国控、国药股份高管人事变动</title>
    <updated>2021-01-13T18:33:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/3nd-cwSU30evcHn6dAtIGA</id>
    <link href="https://mp.weixin.qq.com/s/3nd-cwSU30evcHn6dAtIGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百度、京东入局慢病管理，用户规模成倍增长，市场按下“加速键”</title>
    <updated>2021-01-12T17:09:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/0YekZ0eDH0qMxQCqhDlN0g</id>
    <link href="https://mp.weixin.qq.com/s/0YekZ0eDH0qMxQCqhDlN0g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>手握1.1类新药、独家医保、基药，百万年薪不在话下！</title>
    <updated>2021-01-12T17:09:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/z7cBWRVGDzWAsIGt8mFnKA</id>
    <link href="https://mp.weixin.qq.com/s/z7cBWRVGDzWAsIGt8mFnKA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PD-1最新进展 | 百济神州与诺华海外合作，信迪利单抗第3个适应症上市申请获受理</title>
    <updated>2021-01-12T17:09:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/HYDQKtDVyFu0NH7ouqczxA</id>
    <link href="https://mp.weixin.qq.com/s/HYDQKtDVyFu0NH7ouqczxA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>